M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 10.07.2020 | 11:18

M1 Kliniken AG: Successfully conducts the annual general meeting. Despite temporary losses due to the lock-down, the Management Board confirms its assessment of the company's growth prospects.

DGAP-News: M1 Kliniken AG / Key word(s): AGM/EGM/Miscellaneous
10.07.2020 / 11:18
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG successfully conducts the annual general meeting. Despite temporary losses due to the lock-down, the Management Board confirms its assessment of the company's growth prospects. All proposed resolutions approved by large majorities.

Berlin, 10 July 2020. Yesterday, M1 Kliniken AG successfully held its Annual General Meeting 2020.

In his presentation, the Management Board gave an outline of the company's prosperous development in the 2019 financial year, which was accompanied by a significant expansion of the national and international network of specialist centres. Furthermore, the Management Board described the temporary effects of the corona lock-down from March to May 2020. The loss of two months of sales will lead to a short-term interruption of the previous growth course. However, due to the rapid achievement of very high capacity utilisation rates following the reopening of the specialist centres, the Management Board is convinced that the corona pandemic will not have a negative impact on the further business development of M1 in the medium and long term.

Finally, the Management Board outlined the reasons for the acquisition of a good 48% of the shares in Haemato AG, which should lead to a focusing of both companies and mutual support. The transaction was successfully implemented as of July 1, 2020. As a result of the takeover, the company expects a significant increase in sales and earnings already in the current fiscal year 2020.

A total of 72.9% of the share capital was represented at the Annual General Meeting. The items on the agenda included the resolution on the appropriation of the net profit for 2019, the discharge of the members of the Management Board and Supervisory Board, the re-election of the company's Supervisory Board and the election of the auditor for the 2019 financial year. The resolutions on the agenda of this year's Annual General Meeting were passed with a majority of over 90 %.

The detailed voting results are published at: https://www.m1-kliniken.de/aktie/hauptversammlung.html

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the "M1 Schlossklinik" for plastic and aesthetic surgery in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.


Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


10.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

25. September 2020